Jennifer Lawrence is being open about what she wants after having two kids, including cosmetic surgery. In a recent interview with The Cut, the Hunger Games actress said she just wants to look put together — even when she’s not, which is nothing short of relatable. “I want to be a sexy mom,” she told the outlet. “At drop-off, I want to look like a woman that has her s— together even when I’ve just woken up and don’t have my s— together.” Related story Why Katie Thurston Is Calling Herself a “Human Jack-o’-Lantern” After Her Double Mastectomy ‘Second One, Nothing Bounced Back’ Lawrence, who shares two sons with her husband, Cooke Maroney, first talked about getting her breasts done in an October 2025 interview with The New Yorker. Her youngest was only six months old at the time, and she was planning to have the surgery that November. “Everything bounced back, pretty much, after the first one,” she said, referring to her post-pregnancy body. “Second one, nothing bounced back.” She also expected to film another nude scene the following spring, when she would be about a year postpartum. That gave her a work deadline most moms don’t have to factor into their post-baby plans. But when asked whether she’d still want the surgery if she weren’t a famous actress, she said yes. “Maybe I wouldn’t be hustling to the appointment in the same way,” she said. “But I think yes.” Now, a year later, she’s opening up about life after the surgery. ‘I Want to Be a Sexy Mom’ Lawrence also talked about launching her haircare brand, Mes, and wanting to look good without spending forever getting ready. (Honestly, same.) “I feel like if my hair looks okay, then nobody’s gonna notice anything else about my face, clothes, or body,” she told The Cut. “I also can find myself using it to hide.” If there’s one thing Lawrence has always given us, it’s transparency. Plenty of parents can relate to the chaos of the morning school run, and if breast surgery and a good hair day are what help her feel confident and put together, we’re here for it. Source link
Katie Thurston Shows ‘Glowing’ Breast Implants After Double Mastectomy
Katie Thurston has a surprising discovery to share, and yes, it involves her breast implants. The former Bachelorette posted an Instagram video on Oct. 23 showing what happens when she shines a flashlight against her breast: It appears to glow. Naturally, she had a seasonal caption ready. “Just your human jack-o’-lantern,” she wrote, “checking in after a #doublemastectomy.” Thurston had the surgery in April as part of her treatment for stage 4 breast cancer. Related story Jennifer Lawrence Says Her Post-Baby Breast Surgery Helps Her Feel Like She ‘Has Her S— Together’ at School Drop-Off Why Are Her Implants Glowing? As a plastic surgeon explained to People, light can pass through the saline or silicone inside breast implants. That’s why Thurston’s breast appeared to glow when she held a flashlight against it — and why she’s calling herself a “human jack-o’-lantern.” Jokes aside, Thurston knew the video would get people’s attention and had something she wanted them to hear. “It’s #breastcancerawareness month, so I thought I’d grab your attention,” she wrote. “Don’t wait until you’re 40 to start paying attention to your boobs. How do they look? How do they feel? Any changes should be discussed with your medical team.” ‘I’m in This Room Today Because of Research’ Thurston has been sharing her experience since receiving her breast cancer diagnosis in February 2025. At the Breast Cancer Research Foundation’s Symposium & Awards Luncheon earlier this month, she recalled how quickly her plans with her now-husband, Jeff Arcuri, changed. “At a time we thought we’d be planning our wedding, trying on wedding dresses — instead I had to decide where I’d be for my care,” she said. During her speech, Thurston also announced that she currently has “no evidence of disease.” “When I was first diagnosed as stage four, I thought it was going to be the end of my life. I had no idea what kind of options I was going to have, or how long I was going to live,” she said. “I’m in this room today because of research.” Source link
CDC deputy director steps down after 4 months
October 28, 2026 2 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Jennifer A. Shuford, MD, said she wants to spend more time with family. Reports said she has disagreed with the administration’s stance on vaccines. Jennifer A. Shuford, MD, MPH, resigned as the CDC’s deputy director and chief medical officer after spending just 4 months at the agency. Shuford said she was leaving to spend more time with her family. “I am so thankful to President Trump and Secretary Kennedy for giving me the opportunity to help lead CDC,” she said in a statement provided to Healio. “It has been an amazing experience, and I will be forever grateful for it.” The CDC announced that Jennifer Shuford, MD, resigned from her high-ranking dual role at the agency. T he Washington Post first reported Shuford’s departure. Two anonymous sources told the Post that disagreements over the Trump administration’s vaccine policies factored into her decision to exit the agency. Shuford’s departure comes amid the largest surge in measles cases in the United States since 1991, according to the CDC. During Shuford’s brief stint, the administration continued its efforts to overhaul the childhood immunization schedule and make changes to the MMR vaccine, drawing sharp criticism from public health officials. Satish K. Pillai, MD, MPH, will fill Shuford’s dual role at the CDC on an interim basis, HHS confirmed to Healio. Pillai led the agency’s initial Ebola response in the Democratic Republic of Congo earlier this year but stepped down from that position in late July. HHS said it will begin a search for a permanent successor “in the near future” but did not specify a timeline on when that decision could be made. In a statement, CDC director Erica Schwartz, MD, JD, MPH, commended Shuford’s “outstanding leadership and commitment to the CDC and public health, especially as she has navigated an exceptionally demanding, high-profile, and constantly evolving environment over the past several months.” Anne Schuchat, MD, former principal deputy director and two-time acting director of the CDC, told Healio that the agency will miss Shuford’s veteran public health leadership. “It is always hard to know what may underpin a senior leader’s decision to step down, so I would not want to speculate,” Schuchat said. “But I can say that I had heard that Dr. Shuford was much appreciated by career staff who felt she had brought important state public health experience to the agency’s senior leadership. So, from that perspective it is certainly a loss.” Shuford, whose last day is scheduled for Nov. 12, stepped into her dual role at the CDC in June. She had previously served as the commissioner of the Texas Department of Health and Human Services from 2022 to 2026, leading the state’s response to a measles outbreak in West Texas. For more information: Anne Schuchat, MD, can be reached at infectiousdisease@healio.com. Published by: Sources/Disclosures Source: Healio Interviews References: Disclosures: Schuchat report no relevant financial disclosures. Ask a clinical question and tap into Healio AI’s knowledge base. PubMed, enrolling/recruiting trials, guidelines Clinical Guidance, Healio CME, FDA news Healio’s exclusive daily news coverage of clinical data Learn more Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Source link
Excessive bloating, gas consistent burden for menopausal women, study shows
October 28, 2026 2 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Over 65% of women in one of the three phases of menopause have bloating and gas above the normal severity range. In the study’s next steps, researchers will look at the correlation between GI symptoms and anxiety. Excessive bloating and gas are prevalent gastrointestinal symptoms in women throughout the menopause trajectory, with 65.6% of participants in a new study scoring above the normal severity range. The study, conducted by a research team at the University of Calgary in Alberta, Canada, is aimed at better understanding the relationship between GI issues and anxiety for women in premenopause, perimenopause and postmenopause. “Essentially, [menopausal women] have more severe bloating and gas compared with the normal value that we usually consider,” Sanjana Solomon, the study’s lead author, told Healio. “This was prevalent across all stages, meaning it included premenopause, perimenopause, and postmenopause, so this is something that is seen throughout and not just in a particular stage.” The study included a cohort of 1,832 women aged 40 to 60 years and were premenopausal to postmenopausal. Participants filled out self-reported questionnaires, provided stool and blood samples, underwent physical and cognitive assessments, and participated in qualitative interviews. The researchers analyzed the GI burden in the women and found that 65.6% scored above the normal severity range for bloating and gas, and this result was consistent throughout the menopause trajectory. They found that significantly fewer women scored above the normal range for other GI symptoms like constipation (23.3% above normal), diarrhea (13.6%), pain (19.6%) and nausea (10.2%). Researchers also analyzed anxiety scores in the women, finding that 17.5% of the participants reported moderate to severe anxiety. The study showed that 14.6% of those women were in premenopause, and the prevalence of anxiety rose to around 19% during perimenopause and postmenopause. This is the first phase of a multiyear study to further examine the association of GI symptoms and anxiety in the women in the cohort, according to Solomon. “We hope to bring them in over the subsequent years to repeat these tests to understand how these changes occur in them individually long term and be able to make broader conclusions from that,” Solomon said, noting that is study is meant to establish a “baseline.” The researchers believe there needs to be more investigation to fully understand the underlying mechanisms for GI symptoms and anxiety. The cohort is currently in its second year of testing, and the research team will continue its analysis by investigating the gut microbiota profiles of the study’s participants. “We are trying to understand if these more severe gut symptoms are potentially attributed to more anxiety, or if more anxiety in individuals causes these bloating and gut symptoms,” Solomon said. For more information: Sanjana Solomon can be reached at primarycare@healio.com. Sources/Disclosures Source: Solomon S, et al. Gastrointestinal symptoms are associated with anxiety across the menopause trajectory: Findings from the MOMENTUM Canadian menopause cohort. Presented at: Annual Meeting of the Menopause Society; Oct. 20-24; 2026; San Diego. Disclosures: Solomon reports funding from the Joan Synder Fund for Excellence in Kinesiology Research and the Canadian Institutes of Health Research. Ask a clinical question and tap into Healio AI’s knowledge base. PubMed, enrolling/recruiting trials, guidelines Clinical Guidance, Healio CME, FDA news Healio’s exclusive daily news coverage of clinical data Learn more Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Source link
Saroglitazar favors US patients for PBC response, pruritus relief
October 28, 2026 2 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Saroglitazar showed superior biochemical and pruritus response in U.S. vs. non-U.S. patients with PBC. ALP normalization rates were similar between groups despite greater ALP reductions in U.S. patients. NASHVILLE, Tenn. — Patients in the U.S. with primary biliary cholangitis exhibited greater biochemical response and improvement in pruritus with saroglitazar magnesium than non-U.S. patients, according to data presented here. Despite slightly higher baseline liver enzyme levels for U.S. patients, alkaline phosphatase normalization rates were similar between U.S. and non-U.S. groups. Raj K. Vuppalanchi, MD, FACG, speaks at the podium during ACG Annual Scientific Meeting. Photo: Robert Stott. “Saroglitazar is PPAR-alpha/gamma agonist with an interesting targeting pathway in the pathogenesis of PBC,” Raj K. Vuppalanchi, MD, FACG, director of hepatology at Indiana University School of Medicine, told attendees at ACG Annual Scientific Meeting. “[Saroglitazar primarily acts] as a PPAR-alpha agonist [which] results in beneficial effects through bile acid homeostasis and decreasing cholestatic inflammation. It also has a modest PPAR-gamma effect, which results in potential benefits through anti-inflammatory and possibly antifibrotic effects.” In findings from the phase 2b/3 EPICS-III trial presented at EASL Congress earlier this year, Vuppalanchi and colleagues reported that saroglitazar 1 mg (Zydus Therapeutics) significantly improved biochemical response in patients with PBC. At week 52, 56.7% of patients receiving saroglitazar achieved the primary endpoint, compared with 9.8% on placebo. Complete ALP normalization, the key secondary endpoint, was achieved by 8.2% of patients treated with saroglitazar vs. none who received placebo (P = .016). “To see if patients in the United States have consistent treatment response compared to the rest of the world,” Vuppalanchi and colleagues conducted a post hoc analysis of the EPIC-III trial. The researchers compared outcomes among 42 participants in the U.S. — 28 randomly assigned to saroglitazar and 14 to placebo — with those from 106 participants from outside the U.S., including 69 who received saroglitazar and 37 who received placebo. Baseline demographic and disease characteristics were generally comparable between the regional subgroups, although median baseline ALP was slightly higher among participants in the U.S. compared with non-U.S. participants (302 U/L vs. 287 U/L). At week 52, saroglitazar outperformed placebo for composite biochemical response among both U.S. and non-U.S. participants, with a greater placebo-adjusted treatment difference reported in the U.S. subgroup (60.7% vs. 41.6%). “The primary endpoint that we saw was that composite biochemical response favors saroglitazar in both the U.S. and non-U.S. regions, but the larger treatment difference was seen in the U.S. population,” Vuppalanchi said. At week 52, saroglitazar produced a greater mean reduction in ALP among participants in the U.S. vs. those outside the U.S. (–166.2 U/L vs. –104.7 U/L). However, ALP normalization rates were similar between the subgroups (7.1% vs. 8.7%). At week 24, the treatment difference in 5-D itch score also demonstrated a greater reduction in the U.S. subgroup (–4.4 vs. –2.8). “This exploratory regional analysis of the EPICS-III trial shows saroglitazar favored over placebo in both U.S. and non-U.S. populations, but the treatment differences in the U.S. population were numerically higher compared to the non-U.S. population,” Vuppalanchi said. “Although ALP normalization rates were similar, the treatment differences in the 5-D itch score also appeared to be higher in the U.S. subgroup, and saroglitazar was well tolerated and demonstrated a great safety profile.” Published by: Sources/Disclosures Source: Vuppalanchi RK, et al. Greater treatment response to saroglitazar in US versus non-US patients with primary biliary cholangitis: A geographic subgroup analysis of the phase 3 EPICS-III trial. Presented at: ACG Annual Scientific Meeting; Oct 12-14, 2026; Nashville, Tenn. (hybrid meeting). Disclosures: Vuppalanchi reports an advisory board role with and grant/research support from Takeda Pharmaceuticals and grant/research support from Eli Lilly & Co. and Zydus Therapeutics. Please see the study for all other authors’ relevant financial disclosures. Ask a clinical question and tap into Healio AI’s knowledge base. PubMed, enrolling/recruiting trials, guidelines Clinical Guidance, Healio CME, FDA news Healio’s exclusive daily news coverage of clinical data Learn more Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Source link
Viral hepatitis in pregnancy: Updated guidelines for HBV, antivirals for HCV
October 28, 2026 2 min watch Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio NASHVILLE — In this Healio video, Tatyana Kushner, MD, MSCE, discusses a presentation from the GI Ignite session about viral hepatitis in pregnancy at the ACG Annual Meeting. “It’s an exciting time for viral hepatitis in pregnancy,” Kushner, associate professor of medicine and director of outcomes clinical research in the division of gastroenterology and hepatology at Weill Cornell Medicine, told Healio. In the early morning session, experts talked about updated guidelines from AASLD/IDSA for hepatitis B and hepatitis C treatment with antivirals in pregnancy. Published by: Sources/Disclosures Source: Healio Interviews Disclosures: Kushner reports no relevant financial disclosures. Ask a clinical question and tap into Healio AI’s knowledge base. PubMed, enrolling/recruiting trials, guidelines Clinical Guidance, Healio CME, FDA news Healio’s exclusive daily news coverage of clinical data Learn more Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Source link
Suleika Jaouad & Jon Batiste Share a Loving Hospital Update
Jon Batiste and Suleika Jaouad’s latest update is a small glimpse of love in the middle of a very difficult stretch. In a joint Instagram post shared Oct. 25, the couple cuddled up for two hospital selfies. In one photo, Jaouad, wrapped in a blanket, rested her chin on her husband’s shoulder; in another, she kissed his cheek. “The kids doing alright today, and still madly in love,” they wrote. The post comes nearly a month after The New York Times best-selling author and journalist announced that she needs a third bone marrow transplant. Treatments that had been keeping her leukemia “at bay,” she explained, were “no longer doing the trick.” Related story Why Brandi Glanville Is Having Her ‘Face Taken Off’ to Treat a Suspected Parasite ‘I Have a Great Deal of Hope’ Jaouad shared the news via Instagram on Sept. 28. “I’ve known another bone marrow transplant might be in my future. I was hoping the future was less in a hurry,” she wrote. Jaouad’s leukemia diagnosis came at 22, just as she was starting her life after college. Now 38, she’s already undergone two bone marrow transplants. “I have brilliant doctors I trust with my life,” she wrote in the accompanying Substack post. “I have Jon, and my family, and the kind of friends who show up carrying games and flowers and inappropriate jokes. I have four dogs, two peacocks and fourteen chickens. I have a plan, and I have a great deal of hope.” Then she added, “I am also scared.” Looking for Another Breakthrough Jaouad has been open about how much medical research has already changed her treatment options. “I’ve lived with leukemia for most of my adult life, long enough to watch the horizon of what is possible draw closer,” she wrote. Some treatments she’s received didn’t exist when she was first diagnosed, while others once sounded experimental. She and her family are also raising money to establish the Suleika Jaouad Fund for Leukemia & Stem Cell Transplant Research at Memorial Sloan Kettering Cancer Center. The fund will support work led by her doctors, Eytan Stein and Sergio Giralt, on difficult-to-treat leukemias and more effective bone marrow transplants. Although their latest photo doesn’t offer a medical update, it does show how she and Batiste, who married in 2022, are spending this time together. For now, they’re making time for a kiss and a little humor in a hospital room — and we’re wishing them more moments like this as treatment continues. Source link
Gianna Christine on Finding Independence Through Birth Control
In today’s digital age, social media is filled with health and lifestyle information. For many women, the sheer volume of online information can make it difficult to tell what’s accurate, what’s opinion, and what truly applies to their own lives. Social media content creator and Organon partner Gianna Christine has seen how quickly health information can spread online—and why it’s important to separate personal experience from medical guidance. For her, choosing a treatment comes from discussing questions with a healthcare professional to understand your options. Related story Why the Birth Control Talk Deserves a Spot on Every Back-to-School Checklist Gianna Christine How has building a career online and creating content shaped the way you view health information on social media? Gianna Christine: Building my career on social media has made me hyperaware of the difference between the “highlight reel” and real life. On platforms like Instagram, people see a curated version of me, but on Snapchat, where I share more of my day-to-day life, my audience is interested in my advice. That’s taught me that there’s a responsibility that comes with that trust. When sharing your own experiences and what works for you, it’s important to understand that health decisions are personal, and what works for one person may not be right for another. I’m always clear about that with my followers and suggest women find a doctor they trust to speak to. Has your relationship with social media changed as you’ve gotten older? Gianna: Absolutely. I think when you’re younger, it’s easy to assume that if something is popular online, it must be true. I even experienced this myself, as I almost ruled out certain birth control options entirely because of stories I’d heard on social media. But as I’ve gotten older, I’ve become much more intentional about where I get my information. I always talk with my own healthcare professional if I have any questions or concerns and tell others to do the same. There’s so much health information available online today that it can feel overwhelming for many women. How do you sort through it all and prepare for conversations with your healthcare professional, and what would you tell other women trying to do the same? Gianna: It can definitely feel like information is everywhere, and not all of it may be easy to sort through or understand. What’s worked for me is not trying to become an expert, but showing up prepared. Before an appointment, I write down the questions I want to ask my doctor, such as, “What are all my options?” (not just the one a friend mentioned or the one that’s trending), and “What are the potential side effects I need to know about?” Appointments can go by quickly, so being prepared makes it easier to have a productive conversation and make informed decisions. My biggest advice to other women is to use social media to hear different experiences and feel less alone, but bring your questions and what you’ve heard to your healthcare professional so they can help put it in context for what makes sense for you. You often talk about independence and building a life that aligns with your goals and priorities. How has that mindset influenced the way you approach adulthood and the choices you’ve made about birth control? Gianna: Right now, I’m focused on my career, my friendships, and enjoying this chapter of life. Living in New York has given me the opportunity to invest in myself and pursue goals that are important to me. I’ve realized adulthood isn’t about following someone else’s timeline; it’s about making choices that align with your values and priorities. That mindset has influenced every aspect of how I live my life, including how I approached birth control. My journey with birth control started when I was much younger. I initially tried birth control pills but didn’t want an option I had to take every day. When I spoke with my healthcare professional about other options, she walked me through what was available to me and answered my questions. Ultimately, I chose NEXPLANON® (etonogestrel implant) 68 mg Radiopaque because my doctor and I determined it was right for me. While I may be on NEXPLANON, it’s important for each person to understand their contraception options, how they work, and the Important Safety Information before making a decision with their healthcare professional. NEXPLANON is a long-acting prescription birth control for the prevention of pregnancy in women of reproductive potential for up to 5 years* and is over 99% effective.† *NEXPLANON must be removed by the end of the fifth year.† Less than 1 pregnancy per 100 women who used NEXPLANON for one year. Important Safety Information Don’t use NEXPLANON if you’re pregnant or may be pregnant; have or had blood clots or certain cancers; or have liver disease, liver tumor, or unexplained vaginal bleeding. Immediately after the implant is placed, you and your healthcare provider should feel for it. If at any time you can’t feel the implant, contact your healthcare provider right away and use a non-hormonal birth control method (such as condoms). Removal of the implant may be difficult or impossible if it isn’t where it should be. While uncommon, ectopic pregnancy (occurring outside the womb) can occur, which can cause serious internal bleeding, infertility, and even death. You’re likely to experience changes to your period. NEXPLANON may raise the chance of serious blood clots, which can cause heart attack, stroke, or death, especially if you smoke or have other risk factors. For more information, please see more Important Safety Information below, and click here to read the Prescribing Information, including the Boxed Warning, and the Patient Information, and talk to your healthcare professional. NEXPLANON works by releasing a steady, low dose of the progestin hormone etonogestrel to prevent pregnancy by: Stopping ovulation by preventing your ovaries from releasing an egg Thickening cervical mucus to make it harder for sperm to reach an egg if one were released Changing the uterine
Brandi Glanville Shares Exploratory Facial Surgery Plans
Brandi Glanville’s latest health update sounds frightening, even in her own words. On a recent episode of her Brandi Unfiltered podcast, the Real Housewives of Beverly Hills alum told her co-host, James Maas, that her doctor is “taking my face off on Friday and going to do an exploratory surgery to kind of do a power wash under my skin.” The reality star says she hopes that the exploratory surgery will help explain the strange symptoms she’s been dealing with for the last few years. Related story Jon Bon Jovi Opens Up About His 4-Year ‘Hell’ Recovering From Major Vocal Surgery What Has Glanville Said About Surgery? Glanville said her doctors identified “two definite spots, like either fungal balls or something alive” — she believes the latter. “I think it’s alive personally ‘cause it moves when it wants,” she said. When Maas asked whether the surgeon would be able to peel back her face to examine the spots, Glanville replied, “And he just cuts it out.” Earlier this month, she said doctors planned to examine her eustachian tubes, sinuses, and gums. “They’re going to go in and hopefully put a balloon in my eustachian tubes and clear that out so that everything can drain,” she said at the time. She’s also described hearing and feeling a rattling sensation near her jawline. The changes have left her worried about her health, not just her appearance. “I’m afraid for my health. Like, I don’t know what’s making me sick,” she said. ‘Super Excited’ — and ‘Scared to Death’ Glanville began experiencing symptoms years ago in her face, cheek, and jaw. “Then it went over my head, back in my neck. Now it’s down my spine,” she told Maas. She’s “super excited” to finally get some answers, but “scared to death.” She added, “I’ve never had facial surgery.” There’s the cost to consider, too. She said she would owe $5,000 on top of whatever insurance covered, and friends have started a GoFundMe to help with treatment expenses. After years of symptoms and medical appointments, paying for another procedure adds one more worry. “It’s only been four years,” she said of the ordeal. For now, she’s hoping the surgery will bring answers — and some relief after a long wait. Source link
Sugar in Red Meat Linked to Higher Type 2 Diabetes Risk
A sugar in red meat? That’s probably not what comes to mind when you think about steak. But preliminary research linked a little-known sugar called Neu5Gc to a 63% higher risk of type 2 diabetes. In the observational study, presented at the European Association for the Study of Diabetes meeting in Milan and covered by ScienceDaily on Oct. 18, researchers tracked the diets and health of nearly 90,000 French adults for about seven years. What Is Neu5Gc? Neu5Gc stands for N-glycolylneuraminic acid, a sugar molecule most mammals (except for humans) naturally produce. An ancient mutation in the CMAH gene left us unable to make it ourselves, but we can still absorb it when we eat foods from animals that do. That includes beef and lamb, which are particularly rich sources, as well as dairy products, which contain smaller amounts. Related story Octavia Spencer Found Out She Had Type 2 Diabetes at a Routine Physical in Her 30s, and Here’s What She Changed For this study, researchers looked at Neu5Gc from meat and dairy separately to see whether its source made a difference in diabetes risk. What Did the Study Find? The researchers analyzed data from 89,953 adults in NutriNet-Santé, a French study that follows people’s diets, lifestyles, and health over time. Participants were 42 years old on average, and 79% were women. None had type 2 diabetes or cancer when they joined, but over a median follow-up of 7.2 years, 966 developed type 2 diabetes. Researchers divided participants into five groups based on how much Neu5Gc they got from meat. Compared with those consuming the least, the highest group had a 63% higher diabetes risk, and the second-highest had a 41% higher risk. Neither middle group showed a statistically significant increase. That doesn’t mean 63% of people in the highest group developed diabetes. Their risk was higher compared with people consuming the least. How much red meat does that translate to on a plate? The median daily amounts were: Men in the highest group: 97 grams (3.4 ounces), or 136 grams (4.8 ounces) including processed meat. Women in the highest group: 73 grams (2.6 ounces), or 96 grams (3.4 ounces) including processed meat. People in the lowest group: Men ate 5 grams (0.2 ounces); women ate none. These were typical amounts within each group, not a guide to how much red meat someone can eat without increasing their risk. The findings were also different for dairy. Getting more Neu5Gc from dairy products wasn’t associated with higher diabetes risk, possibly because cow’s milk contains much less of the sugar. Across all sources, the highest group had 37% higher risk, mainly driven by meat. “Our findings support chronic inflammation as a specific mechanism linking red meat consumption with T2D, partly beyond the amount of red meat a person eats and partly independent of body fat,” lead author Dr. Leopold Fezeu of Université Sorbonne Paris Nord said in the study release. How Was Intake Measured? Participants recorded everything they ate and drank over three separate 24-hour periods. Researchers used a validated food database to estimate daily Neu5Gc from meat versus dairy. Red meat included beef, lamb, pork, rabbit, goat, and game. They tracked processed meats, such as bacon, sausages, and cured meats, separately. What Could Explain the Link? Neu5Gc can become part of our tissues, but our immune system may still recognize it as foreign. Dr. Hana Kahleova, director of clinical research at the Physicians Committee for Responsible Medicine, compares the proposed response to a smoke alarm that keeps going off. “One false alarm does no harm. When it beeps meal after meal, year after year, the body lives in a state of low-grade alert,” she tells SheKnows. “Researchers call this xenosialitis: inflammation triggered by a foreign sugar sitting in our own tissues.” Researchers have linked this response to heart disease and cancer. They suspect it could also make the body less responsive to insulin and put extra stress on the cells that produce it, but that explanation is still a hypothesis. “We have not yet shown in people that Neu5Gc inflames the pancreas or other insulin-sensitive tissues directly,” says Dr. Kahleova. Other factors could contribute, too: Age, sex, activity, diet, smoking, and existing conditions didn’t fully explain the link. Accounting for body mass index (BMI) weakened the association, though it remained statistically significant. Developing obesity explained an estimated 13% of the association. Would swapping beef or lamb for poultry or plant proteins help? This study didn’t test that. Researchers plan to measure anti-Neu5Gc antibodies and examine interactions with heme iron, a form of iron in meat. There’s no peer-reviewed paper yet; the authors say their estimates could change, and researchers don’t know how much Neu5Gc it takes to trigger an immune response. Until the full study is published and other researchers can weigh in, these findings are best seen as a reason to keep watching the research, not a reason to panic. If you’re worried about your own diabetes risk or how much red meat you eat, talk with your doctor or a registered dietitian. Source link